Background: Because high serum low-density lipoprotein (LDL) and total cholesterol concentrations before treatment have been found to be significant positive prognostic factors for a sustained virological response to HCV therapy in monoinfected patients, the aim of this study was to assess this relationship in HIV-HCVcoinfected patients. There is growing evidence of interdependence between HCV infection and lipid metabolism [1] . Indeed, several data suggest that the low-density lipoprotein (LDL) receptor is one of the receptors implicated in HCV replication. HCV enters target cells in a slow complex multistep process involving the presence of several entry factors [2, 3] . Initial attachment involves glycosaminoglycans and the LDL receptor, with in vitro competitive inhibition of HCV binding by LDL [1] . In addition, stored lipids and cytosolic lipid droplets have also been shown to be crucial structures that form platforms for viral replication and assembly. The formation of lipid-associated viral particles also requires a functional lipoprotein secretion pathway.
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Nevertheless, in HCV-monoinfected patients, high serum LDL and cholesterol concentrations before treatment were found to be a significant positive prognostic factor for a sustained virological response to HCV therapy, in particular for genotypes 1 and 2 [4, 5] . In HIV-HCV-coinfected patients, high total or LDL cholesterol concentration was also shown to predict a sustained virological response to HCV therapy in three recent retrospective studies [6, 7] .
This point is of great importance. First, it could improve accuracy in predicting the virological response and help doctors to select patients and to decide how patients should be treated for HCV. Second, it could be speculated that antiretroviral associations that increase levels of LDL cholesterol (protease inhibitor [PI]-based combinations) might also increase the rate of virological response [6] 
Introduction

Methods
In order to better assess the potential effect of lipid profiles on the response to HCV therapy in HIV-HCVcoinfected patients, a complementary study was conducted in patients included in the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC02-Ribavic therapeutic trial. The results of this trial have been reported elsewhere [8] . Briefly, HIV-HCVcoinfected patients who had never received interferon or ribavirin were randomly assigned to receive either weekly subcutaneous injections of 1.5 µg/kg pegylated interferon-α2b (ViraferonPeg ® ; Schering-Plough, Kenilworth, NJ, USA) plus 800 mg ribavirin (Rebetol ® ; Schering-Plough) daily or subcutaneous injections of 3 MU of interferon-α2b thrice weekly plus 800 mg ribavirin daily for 48 weeks. Patients were eligible for the trial if they had detectable serum HCV RNA, interpretable results of liver biopsy performed within the previous 18 months and showed at least mild activity or fibrosis, a CD4 + T-cell count >200 cells/mm 3 , stable HIV RNA at randomization and stable or no antiretroviral treatment during the previous 3 months. The main exclusion criteria were active consumption of illicit drugs, excessive alcohol intake (>40 g/day for women and 50 g/day for men), decompensated cirrhosis and positive hepatitis B surface antigenaemia. The biopsies were scored in parallel by two experienced pathologists blinded to the diagnosis, as described previously [8] .
For the present study, patients who received at least one dose of HCV therapy in the trial and who had available sera at baseline (that is, sampled before HCV therapy and stored at -80°C) were enrolled. Total cholesterol, LDL, high-density lipoprotein (HDL), triglyceride (TG) and apolipoprotein B (apoB) concentrations in these sera were measured at baseline. Total cholesterol and HDL, TG and apoB concentrations were measured on a Dimension analyser with appropriate reagents (Dade-Behring, Newark, NE, USA). ApoB was measured by immunoturbidimetry.
Comparisons between continuous variables were done using the Mann-Whitney U test and percentages were compared using the χ 2 test. A logistic regression model was used to identify associations between a sustained virological response (outcome variable) and pretreatment characteristics (input variables, such as lipid concentrations), including the HCV genotype and the type of interferon (pegylated or not). All statistical tests were two-sided, with a type I error of 5%.
Results
A total of 315 patients out of the 383 patients who took at least one dose of treatment were enrolled. 
Discussion
In our study, the associations between lipid parameters and liver histology are consistent with previous data. Indeed, the correlations we observed with steatosis/ steatohepatitis are similar to those observed in HCVmonoinfected patients, except for apoB [9] . A negative correlation between steatosis and total LDL and HDL cholesterol was found (although the correlation coefficient value [r] was quite low), which is in accordance with several studies showing a significant relationship between steatosis and hypobetalipoproteinaemia independently of other factors [10, 11] . Indeed, the microsomal TG transfer protein (MTP) is necessary for the assembly and secretion of very low-density lipoprotein (VLDL) from hepatocytes. Perlemuter et al. [12] showed that hepatic overexpression of HCV core protein interferes with the hepatic assembly and secretion of VLDL and inhibits MTP activity. Our results, which show that total cholesterol and LDL cholesterol correlated negatively with steatosis, are thus likely to be explained by this direct action of HCV core protein on MTP function. By contrast, as steatohepatitis is a risk factor for fibrosis evolution, it could be speculated that cholesterol levels would also correlate negatively with the stage of fibrosis, which was not observed in our study (only for HDL). Out of interest, and according to our results, cholesterol, HDL and LDL levels are not included in most fibrosis blood tests, except for the Forns index.
Although lipid parameters correlated with HCV viral load for HCV genotype 3, they did not appear to be significant predictors of a virological response to interferon plus ribavirin in HIV-HCV-coinfected patients, regardless of the HCV genotype. This contrasts with what is observed in HCV-monoinfected patients [4, 5] and is also partly discordant with the results of a few other retrospective studies focusing on this topic in HIV-infected patients [6, 7] . Indeed, as in our prospective study, no significant difference in lipid concentrations was found between virological responders and non-responders in these latter studies. By contrast, a statistically significant positive correlation between LDL concentration >100 mg/dl and a sustained virological response to HCV therapy was observed for HCV genotypes 1-4 (adjusted odds ratio 2.19 [95% confidence interval 1.04-4.66], P=0.04 [6] and 6.62 [1.97-22 .19], P=0.002 [7] ). We failed to find such a positive association and even observed a trend towards an inverse correlation, regardless of the HCV genotype.
Several particularities could explain these differences. First, the median lipid concentrations in our study were lower than those often observed in HCV-monoinfected patients. This is rather surprising because most of our patients were on HAART and were not treated with lipid lowering drugs; however, the dietary habits of these patients were not investigated. Although blood samples were stored at -80°C, we cannot rule out that this could have led to a slight variation in lipid concentrations; however, it can be advocated that the variation would have been the same for all the patients of the trial and, thus, would not significantly modify the results of our study. Nevertheless, as only 11% of patients had LDL levels above the threshold of 100 mg/dl retrospectively defined and used in previous studies [6, 7] , an effect of high LDL levels on virological response cannot be excluded. Moreover, the potential specific effect of each antiretroviral drug was not specifically assessed in our study. The low rate of virological response in our patients might also have precluded significant differences, with nearly half of the patients on standard interferon-based HCV therapy. However, the large number of patients enrolled allowed us to find or confirm many prognostic factors for a virological response from these same patients (such as the type of interferon treatment, HCV genotype, HCV viral load, transaminase levels, α-fetoprotein levels, the lack of PI-or NNRTI-based antiretroviral therapy or the role of abacavir) [8] . As we found no correlation between lipid concentrations and the virological response despite adjustment for these known confounding factors, the effect of lipids on the virological response, if any, is likely to be weaker than that of these factors.
Our results might also suggest that HIV infection and antiretroviral therapy alter lipid metabolism by different pathways from that observed in HCV-monoinfected patients. Indeed, in a previous study in HIV-infected patients, we observed that HIV lipodystrophy was associated with lower expression of the LDL receptor [13] . Because the LDL receptor could be an entry receptor that allows HCV into hepatocytes, it might be advocated that lower expression of the LDL receptor would 'naturally' enhance the likelihood of a virological response, especially because LDL is frequently increased and, thus, might compete with HCV. In actual fact, HCV viral loads are found to be higher in HIV-HCV-coinfected than in HCV-monoinfected patients [14] , and response rates to HCV therapy significantly worse, even in the HAART era. Lastly, stored lipids and cytosolic lipid droplets have also been shown to be crucial structures that form platforms for viral replication and assembly. The formation of the lipid-associated viral particles also requires a functional lipoprotein secretion pathway.
In conclusion, lipid parameters do not seem to be a strong indicator of fibrosis and, in contrast to other previous studies, they do not appear to be predictors of a response to anti-HCV therapy in our population of HIV-HCV-coinfected patients. The relationship between HCV and the LDL receptor might indeed be modified and/or the potential effect of lipid metabolism on virological response might be outweighed by other factors (HIV-specific or not), which still deserve full attention. Considering these discordances, the issue of a potential positive effect of associations of antiretrovirals that increase levels of LDL cholesterol should be addressed by prospective trials.
